Verona Pharma Ltd (VRNA) Kazanmak

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases with unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The firm has evaluated nebulized Ohtuvayre in its Phase III clinical program ENHANCE (Ensifentrine as an Inhaled Nebulized COPD therapy) for COPD maintenance treatment. The company has developed formulations of ensifentrine for the three inhalation devices: nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. The firm's subsidiaries include Verona Pharma, Inc. and Verona Pharma Ireland Limited.